Information portal on various topics of management of public resources of the Portuguese State

Project sheet

Name

Assistant Researcher in the scientific area of Medical and Health Sciences/Clinical Medicine

Total project amount

246,79 thousand €

Amount paid

0 €

Non-refundable funding

246,79 thousand €

Loan funding

0 €

Start date

01.02.2025

Expected end date

31.03.2026

Dimension

Resilience

Component

Qualifications and Skills

Investment

Science Plus Training

Operation code

02/C06-i06/2024.P2023.14811.TENURE.006

Summary

This position is for an Assistant Researcher of the scientific research career, in the scientific domain/area of Medical and Health Sciences/Clinical Medicine. The Assistant Researcher will be integrated into the Clinical Research Unit of the IPO Porto Research Center (CI-IPOP), specifically into the Early Phase Clinical Trials Unit/Center for Innovative Therapeutics in Oncology (CITO), hosted by IPO Porto.Following Europe’s Beating Cancer Plan and the Mission on Cancer, it is mandatory to establish a Portuguese clinical cancer research program and enroll more patients in research protocols, particularly in clinical trials. The Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), an accredited and well-developed CCC, is in a privileged position to trigger the establishment of a national Precision Cancer Medicine (PCM) ecosystem through long-term partnerships with other national research centers that are willing to collaborate. Moreover, IPO Porto has its own Precision Oncology Program (POP-IPOP) and Molecular Tumor Board (MTB), aiming to have these expanded into a Precision Oncology Platform, with the dual purpose of promoting equitable and widespread implementation of PCM in Portugal and de-risking the development of PCM diagnostics and therapies in the future.To pursue that, a highly qualified and experienced multidisciplinary team is needed, including an Assistant Researcher with proven experience in PCM. The Assistant Researcher to be hired will be responsible for coordinating, managing, and monitoring the main activities related to the Precision Oncology Platform. This will include: cooperating with partner institutions to develop collaborative protocols; evaluating and ranking clinical trial proposals (mainly biomarker-driven projects) regarding innovation potential, feasibility, and strategic relevance to the P.CCC; preparing scientific reports and (white) papers on PCM; promoting patient literacy on several aspects of PCM and awareness regarding clinical research; collaborating with specific work packages of European-funded PCM-related projects at IPO Porto; supervising and mentoring young researchers; and interacting with pharmaceutical and biotech companies to attract further investment.To be eligible for this position, the Assistant Researcher should have a robust track record in PCM and clinical trials, namely: Ph.D. in Biomedicine/Biomedical Sciences or related areas for more than 5 years (and up to 10 years); at least 5 years of clinical research experience as a clinical research coordinator in an Oncology Center; proven participation and expertise in MTB, with proficiency in the use of clinical decision support systems; knowledge in clinical research and drug development dynamics, specifically in phase 1 clinical trials in oncology; experience in cancer translational research, namely biomarkers studies. Hiring a candidate with this profile will strongly reinforce the multidisciplinary team required to the establishment and development of a sustainable PCM ecosystem in Portugal and to help build and reinforce mutual connections with European partners. All the above-mentioned activities will be catalysts for novel initiatives to improve patient care, increase research activity, and create commercial opportunities.

Beneficiaries

Within the scope of the Recovery and Resilience Plan, two types of beneficiaries are responsible for carrying out the projects and using the funding provided. Due to their similar role, the reference to these two types of beneficiaries has been simplified and unified under the term "Beneficiary".
The two types are::
  • Direct Beneficiaries are those whose funding and projects to implement are part of the Recovery and Resilience Plan that has been negotiated and approved by the European Union;
  • Final Beneficiaries are those whose funding and projects to implement are approved following a selection process through Calls for Applications.

Call for applications

As part of the Call for Applications, submissions are requested to select the projects and final beneficiaries to whom funding will be awarded. Specific selection criteria are defined for each call, which must be reflected in the applications submitted and assessed.

The project is appraised on the basis of its compliance with the selection criteria laid down in the calls for applications, and a final score may be awarded, where applicable.

Final evaluation score

8,4
Important note

The components for calculating the assessment score can be found in the selection criteria document mentioned below.

Selection criteria

The funding selection criteria to which this project and its final beneficiary were subject and its score can be found in detail on the Recuperar Portugal platform.

Beneficiaries

Intermediate beneficiaries

Beneficiaries

Procurement

Beneficiaries representing public entities implement their project by signing one or more contracts with suppliers for goods or services through public procurement procedures.

To ensure and provide the utmost transparency in all these contracts, a list of the contracts that were signed under this project is available here, along with the information available on the Base.Gov platform. Please note that, according to the legislation in force at the time the contract was signed, some exceptions do not require the publication of the contracts signed on this platform, and, therefore, no information is available in such cases.

Geographic distribution

246,79 thousand €

Total amount of the project

Where was the money spent

By county

1 county financed .

  • Porto 246,79 thousand € ,
Source EMRP
10.02.2026
All themes
Transparency without leading